...at country’s leading pharmaceutical company, world reputed Square Pharmaceuticals Limited (SPL) and was placed under one of the most important departments in the company Product Management Department (PMD). I have found the experience to be quite interesting and under the guidance of my supervisors and with the help of all the members of the department I have tried my level best to prepare an effective report on the above mentioned topic. The report contains the trend analysis of generic shifting, the reasons behind it and future potentiality of certain generic shifting events and SPL’s planning in the present scenario. Here I have gathered data and information through actual interviews of product managers and secondary data from IMS software and Research department of the organization (MRPC). I honestly hope that my analysis will help to give the idea how generic shifting event occur in the pharmaceutical market in Bangladesh and performance of different brands of different generics in the market. I hope you will find this report worth all the labor I have...
Words: 26333 - Pages: 106
...territory and product structuring, field alignment and related queries. * Making reports regarding performance of our products with their competitors * For launching new products, provide suitable and potential information to the marketing staff about the molecule and segments as well as highlight those areas where we have boost our business. * Make monthly reports brick wise performance , Territory wise performance ,Product wise performance ,Regions and District wise performance , Outlet wise performance * Besides making above reports, different kind of reports are developed as per the requirement of immediate boss * Using Software PLD( Pharmacy Level Data) * Using Software Sales Analyzer * Using Software IMS Plus * Using IMS Black book Organization : Helix Pharma (Private ) Limited. Over All Duration : Jan 2012 up March 2014 Previous Designation : Sales Analysis Officer Previous Responsibilities: * As a Marketing Sales Analyst, My Responsibilities Includes...
Words: 657 - Pages: 3
...great absentees of the social media. Out of fifty pharmaceuticals included in a social media use study, only ten had an identifiable presence on social media. Several articles had been written about what they call the "PharmaSocmephobia." A very interesting study from IMS Institute dedicates over 40 pages to explore, discuss and analyze the reasons, the pros and cons of this behavior. By ignoring social media pharmaceuticals are missing on great information for product development, key opinion leader identification and monitoring. Social media are a tool to listen to customer ideas and feedback, and collaborate with social groups to test products and services. As stated by IMS Pharmaceutical companies cannot afford to delay their entry into these ever evolving and increasingly significant new channels of communication. "Early movers will test the water with an educated trial and error approach and discover benefits for the company as a whole while moving closer to consumers and patients."(Social, 2014) Hard copies of healthcare information decreased in importance while online researchers for healthcare information went from 25% on 2000 to 72% of Americans and 82% among Europeans on 2012 according to IMS study. It is mandatory by FDA when advertising healthcare products FDA to include risk information in the main body...
Words: 516 - Pages: 3
...Valuation Analysis Cost of Capital Intrinsic Valuations Appendices Appendix A Appendix B Appendix C Appendix D References 2 5 14 25 28 37 41 44 46 57 57 60 66 69 72 -1- EXECUTIVE SUMMARY Investment Recommendation: Over-valued, Sell TIF – NYSE 52 week range Revenue (2004) Market Capitalization Shares Outstanding Dividend Yield 3-month Avg Daily Trading Volume Percent Institutional Ownership Book Value Per Share (mrq) ROE ROA Est. 5 year EPS Growth Rate Cost of Capital Est. R2 Ke Estimated 5-year .3175 3-year .5676 2-year .4929 Published Kd WACC Beta 2.59 2.17 2.86 2.071 $33.37 $27.00-41.63 $2.2 Bil. $4.86 Bil 145,730,000 .72% 1,186,500 90.29% $2.84 19.36% 11.81% 11.30% Ke 12.34% 12.34% 11.13% 10.11% 10.79% 3.09% 8.77% EPS Forecast FYE 1/31 EPS 4/1/05 2004(A) $1.48 2005E $1.66 2006E $1.89 2007E $2.12 Industry 14.11 12.09 .96 1.51 Ratio Comparison Trailing P/E Forward P/E Forward PEG M/B Tiffany 16.02 19.22 1.49 2.89 Valuation Estimates Actual Current Price Ratio Based Valuations P/E Trailing P/E Forward PEG Forward Dividend Yield M/B Ford Epic Valuation Intrinsic Valuations Discounted Dividends Free Cash Flows Residual Income Abnormal Earnings Growth Long-Run Residual Income Perpetuity $33.37 $19.47 $30.50 $13.21 N/A $14.40 $35.94 $1.60 $14.84 $12.35 $13.84 $17.13 -2- Tiffany & Co. is established as one of the world’s top retailers of fine jewelry and other luxury items....
Words: 22702 - Pages: 91
...a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap aq ar as at au av aw ax ay az ba bb bc bd be bf bg bh bi bj bk bl bm bn bo bp bq br bs bt bu bv bw bx by bz ca cb cc cd ce cf cg ch ci cj ck cl cm cn co cp cq cr cs ct cu cv cw cx cy cz da db dc dd de df dg dh di dj dk dl dm dn do dp dq dr ds dt du dv dw dx dy dz ea eb ec ed ee ef eg eh ei ej ek el em en eo ep eq er es et eu ev ew ex ey ez fa fb fc fd fe ff fg fh fi fj fk fl fm fn fo fp fq fr fs ft fu fv fw fx fy fz ga gb gc gd ge gf gg gh gi gj gk gl gm gn go gp gq gr gs gt gu gv gw gx gy gz ha hb hc hd he hf hg hh hi hj hk hl hm hn ho hp hq hr hs ht hu hv hw hx hy hz ia ib ic id ie if ig ih ii ij ik il im in io ip iq ir is it iu iv iw ix iy iz ja jb jc jd je jf jg jh ji jj jk jl jm jn jo jp jq jr js jt ju jv jw jx jy jz ka kb kc kd ke kf kg kh ki kj kk kl km kn ko kp kq kr ks kt ku kv kw kx ky kz la lb lc ld le lf lg lh li lj lk ll lm ln lo lp lq lr ls lt lu lv lw lx ly lz ma mb mc md me mf mg mh mi mj mk ml mm mn mo mp mq mr ms mt mu mv mw mx my mz na nb nc nd ne nf ng nh ni nj nk nl nm nn no np nq nr ns nt nu nv nw nx ny nz oa ob oc od oe of og oh oi oj ok ol om on oo op oq or os ot ou ov ow ox oy oz pa pb pc pd pe pf pg ph pi pj pk pl pm pn po pp pq pr ps pt pu pv pw px py pz qa qb qc qd qe qf qg qh qi qj qk ql qm qn qo qp qq qr qs qt qu qv qw qx qy qz ra rb rc rd re rf rg rh ri rj rk rl rm rn ro rp rq rr rs rt ru rv rw rx ry rz sa sb sc sd se sf sg sh si sj sk sl sm sn so...
Words: 29642 - Pages: 119
...Unlock your verbal edge for success Dr. J. Michael Bennett with Paul R. Scheele Million Dollar Vocabulary Million Dollar Vocabulary Playbook The course manual is for your personal use only and is to be used with the six audio recordings from the Million Dollar Vocabulary Personal Learning Course. All worldwide rights are reserved and exclusively owned by Learning Strategies Corporation. No part of this publication may be reproduced or distributed in part or in whole in any form or by any means, or stored in a database or retrieval system, without the prior written permission of Learning Strategies Corporation. Copyright 1999 by Learning Strategies Corporation “Paraliminal,” “Natural Brilliance,” “PhotoReading,” “EasyLearn,” “Personal Celebration,” and “Accelements” are exclusive trademarks of Learning Strategies Corporation worldwide. “Spring Forest Qigong” is a registered trademark of Chunyi Lin. “Diamond Feng Shui” and the Diamond Feng Shui Diamond are trademarks of Marie Vyncke-Diamond. ISBN 13: 978-0-925480-64-4 ISBN 10: 0-925480-64-9 FIRST EDITION June 1999 Printed in the United States of America For coaching and additional support, visit our online Discussion Forum at www.LearningStrategies.com Learning Strategies Corporation Innovating ways for you to experience your potential 2000 Plymouth Road Minnetonka, Minnesota 55305-2335 USA Toll-Free 1-888-800-2688 • 1-952-767-9800 Fax 1-952-475-2373 Mail@LearningStrategies.com www.LearningStrategies.com v042507 ...
Words: 32269 - Pages: 130
...UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ፤ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended September 30, 2014. អ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to . or Commission file number 333-172973 1MAY200918354900 NBTY, Inc. (Exact name of registrant as specified in its charter) DELAWARE (State or other jurisdiction of incorporation or organization) 11-2228617 (I.R.S. Employer Identification No.) 2100 Smithtown Avenue Ronkonkoma, New York (Address of principal executive offices) 11779 (Zip Code) (631) 567-9500 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: None Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes អ No ፤ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ፤ No អ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)...
Words: 83058 - Pages: 333